0.2199

14.97% -0.0387

AIM ImmunoTech Inc (AIM)

Overview News Price History Discussions Forecast Stock Split

AIM ImmunoTech Inc stock is traded at $0.2199, with a volume of 1.80M. It is down -14.97% in the last 24 hours and down -17.33% over the past month. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Previous Close:

$0.2586

Open:

$0.25

24h Volume:

1.80M

Relative Volume:

0.07

Market Cap:

$6.10M

Revenue:

$94,000

Net Income/Loss:

$-13.28M

P/E Ratio:

-0.0301

EPS:

-7.2965

Net Cash Flow:

$-11.67M

1W Performance:

-22.95%

1M Performance:

-17.33%

6M Performance:

-82.41%

1Y Performance:

-91.44%

1-Day Range:

$0.1901

$0.2597

1-Week Range:

$0.1901

$0.28

52-Week Range:

$0.1901

$2.977

AIM ImmunoTech Inc Stock (AIM) Company Profile

Name

AIM ImmunoTech Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

352 448 7797

Address

2117 SW Highway 484, Ocala, FL

Employee

Twitter

@AIMImmuno

Next Earnings Date

2026-08-13

Latest SEC Filings

AIM's Discussions on Twitter

Compare AIM vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AIM AIM ImmunoTech Inc	0.2199	7.13M	94,000	-13.28M	-11.67M	-7.2965
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

AIM ImmunoTech Inc Stock (AIM) Latest News

Aug 13, 2026

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits

Aug 13, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail

Aug 13, 2026

Why Did AIM Stock Plummet 35% Today? - Stocktwits

Aug 13, 2026

Aug 12, 2026

Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo

Aug 12, 2026

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times

Aug 12, 2026

AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan

Aug 12, 2026

Aug 11, 2026

Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria

Aug 11, 2026

Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense

Aug 11, 2026

Aug 10, 2026

AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet

Aug 10, 2026

Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia

Aug 10, 2026

AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade

Aug 10, 2026

AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver Quantitative

Aug 10, 2026

AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView

Aug 10, 2026

AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan

Aug 10, 2026

Aug 07, 2026

AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan

Aug 07, 2026

AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 07, 2026